weixin.sogou.com·· 10 hours agoScore92
HORIZON-Breast06: SHR-A1811 Extends Median PFS to 16.6 Months Versus Chemotherapy in Chemotherapy-Naive HER2-Low Advanced Breast Cancer
In brief
The randomized phase III HORIZON-Breast06 trial of SHR-A1811 (recombinant anti-HER2 ADC, reclertamab ravtansine refer source: rekombinant) met both dual primary PFS endpoints. Results were presented at the 2026 ESMO meeting as LBA13 and published simultaneously in JAMA.
Source: weixin.sogou.com · weixin.sogou.com